In Vivo and In Vitro Suppression of Hepatocellular Carcinoma by EF24, a Curcumin Analog

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Liu, Haitao ^a   Liang, Yingjian ^a   Wang, Luoluo ^a   Tian, Lantian ^a   Song, Ruipeng ^a   Han, Tianwen ^a   Pan, Shangha ^a   Liu, Lianxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PIPERIDONES; TUMOR BURDEN; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868285129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048075     Document Type: Article

References (53)

1. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, et al. (1983) Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 51: 863-877.
2. Jeal A, Ward E, Hao Y, Thun M, (2005) Trends in the leading causes of death in the United States, 1970-2002. Journal of the American Medical Association 294: 1255-1259.
3. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, et al. (2010) Hepatocellular carcinoma (hcc): a global perspective. J Clin Gastroenterol 44: 239-245.
4. Bosch FX, Ribes J, Díaz M, Cléries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
5. Sherman M, (2005) Hepatocellular cancinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154.
6. United States, National Institutes of Health, National Cancer Institute (nci). Cancer Trends Progress Report-2009/2010 Update. Bethesda: nci; 2010.
7. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
8. Thoppil RJ, Bishayee A, (2011) Terpenoids as potential chemopreventive and therapeutic agents in liver cancer World J Hepatol. 3: 228-249.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
10. Lu SC, (2010) Where are we in the chemoprevention of hepatocellular carcinoma? Hepatology 51: 734-736.
11. Je Y, Schutz FA, Choueiri TK, (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and metaanalysis of clinical trials. Lancet Oncol 10: 967-974.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
13. Aggarwal BB, Shishodia S, (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
14. Russo GL, (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74: 533-544.
15. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG, (2008) Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15: 1044-1071.
16. Kaefer CM, Milner JA, (2008) The role of herbs and spices in cancer prevention. J Nutr Biochem 19: 347-361.
17. Moiseeva EP, Manson MM, (2009) Dietary chemopreventive phytochemicals: too little or too much? Cancer Prev Res (Phila) 2: 611-616.
18. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, et al. (2002) Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113Suppl 9B: 71S-88S.
19. Riboli E, Norat T, (2003) Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 78: 559S-569S.
20. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR, 2007.
21. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB, (2008) Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267: 133-164.
22. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, et al. (2006) Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15: 1557-1562.
23. Choi H, Chun YS, Kim SW, Kim MS, Park JW, (2006) Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664-1671.
24. Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, et al. (2006) Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci 1089: 268-275.
25. Aggarwal BB, Kumar A, Bharti AC, (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398.
26. Liang Y, Yin D, Zheng T, Wang J, Meng X, et al. (2011) Diphenyl Difluoroketone: A Potent Chemotherapy Candidate for Human Hepatocellular Carcinoma. Plos One 6: e23908.
27. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
28. Buhrow SA, Reid JM, Jia L, Mamoru SJ, Snyder JP, et al. (2005) LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993). AACR Meeting Abstracts 2005 2005: 984-a.
29. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, et al. (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents. Bioorg Med Chem 12: 3871-3883.
30. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, et al. (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282: 28609-28618.
31. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, et al. (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7: 2409-2417.
32. Thomas SL, Zhao J, Li Z, Lou B, Du Y, et al. (2010) Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 80: 1309-1316.
33. Subramaniam D, May R, Sureban SM, Lee KB, George R, et al. (2008) Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 68: 1962-1969.
34. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, et al. (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263-275.
35. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, et al. (2008) Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 16: 185-197.
36. Zhou Y, Zheng S, Lin J, Zhang QJ, Chen A (2007) The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARγ in rat activated hepatic stellate cell in vitro. Laboratory Investigation 87, 488-498.
37. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB, (2002) PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy. J Biol Chem. 277: 5484-5489.
38. Agarwal ML, Agarwal A, Taylor WR, Stark GR, (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts Proc. Natl Acad Sci U S A. 92: 8493-8497.
39. Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
40. Coqueret O, (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65-70.
41. Kluck RM, Bossy WE, Green DR, Newmeyer DD, (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136.
42. Wang X, (2001) The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933.
43. de Groot RP, Coffer PJ, Koenderman L, (1998) Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal 10: 619-628.
44. Malemud CJ, (2007) Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr Opin Pharmacol 7: 339-343.
45. Morrison DK, Davis RJ, (2003) Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 19: 91-118.
46. Rennefahrt U, Janakiraman M, Ollinger R, Troppmair J, (2005) Stress kinase signaling in cancer: fact or fiction? Cancer Lett 217: 1-9.
47. Chen A, Xu J, Johnson AC, (2006) Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor, Egr-1. Oncogene 25: 278-287.
48. Krystal GW, Sulanke G, Litz J, (2002) Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy. Mol Cancer Ther 1: 913-922.
49. Liu X, Shi Y, Giranda VL, Luo Y, (2006) Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 5: 494-501.
50. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, et al. (2000) Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164: 820-825.
51. Kern MA, Hauqq AM, Koch AF, Schilling T, Breuhahn K, et al. (2006) Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular carcinoma. Cancer Res 66: 7059-7066.
52. Liu F, Wang P, Jiang X, Tan G, Qiao H, et al. (2008) Antisense hypoxiainducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99: 2055-2061.
53. Wang J, Ma Y, Jiang H, Zhu H, Liu L, et al. (2011) Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. Journal of Hepatology 55: 359-368.